Secukinumab showed superior efficacy over etanercept in clearing skin, according to pivotal Novartis Phase III psoriasis results presented at EADV

Novartis has nnounced the results from the head-to-head Phase III FIXTURE study showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, showed superior efficacy to etanercept in moderate-to-severe plaque psoriasis1. Etanercept is a NICE-approved anti-tumour necrosis factor (anti-TNF) therapy, used to treat moderate-to-severe plaque psoriasis2. These significant results are being presented today at the 22nd Congress of the European Association of Dermatology and Venereology (EADV) in Istanbul, Turkey1...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Eczema / Psoriasis Source Type: news